Abstract
Intravascular large B-cell lymphoma (IVLBCL) is characterized by an intraluminal proliferation of lymphoma cells, which frequently causes vascular occlusive disorders in the central nervous system (CNS) [ [1] Ferreri A.J. Campo E. Seymour J.F. Willemze R Ilariucci F Ambrosetti A et al. Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the ‘cutaneous variant’. Br J Haematol. 2004; 127: 173-183 Crossref PubMed Scopus (481) Google Scholar ]. Although the advent of rituximab has improved the survival of patients with B-cell lymphoma [ [2] Takahashi H. Tomita N. Yokoyama M. Tsunoda S Yano T Murayama K et al. Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era. Cancer. 2012; 118: 4166-4172 Crossref PubMed Scopus (63) Google Scholar ], the treatment for neurological deficits caused by IVLBCL-associated angiopathy has not yet been established. Here, we report a patient with CNS-IVLBCL, responding to subacute heparin administration.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
